Trial · NCT07913503
Inspiratory Muscle Training and Diaphragmatic Breathing in GAD
NCT07913503, Not applicable, Recruiting, Saglik Bilimleri Universitesi
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Inspiratory Muscle Training and Diaphragmatic Breathing in GAD. Trials, record NCT07913503. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913503
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inspiratory Muscle Training and Diaphragmatic Breathing in GAD
- NCT number
- NCT07913503
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 51 participants, estimated
- Lead sponsor
- Saglik Bilimleri Universitesi
- Conditions
- Generalized Anxiety Disorder (GAD)
- Interventions
- Inspiratory Muscle Training, Diaphragmatic Breathing Exercises, Progressive Muscle Relaxation
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Anxiety Severity Measured by the GAD-7 | Baseline (week 1) and at the end of the intervention (week 8). | Anxiety severity will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report questionnaire assessing anxiety symptoms over the previous two weeks. Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. The change in total score from baseline to the end of the intervention will be evaluated. |
| Secondary | Change in Forced Vital Capacity (FVC) | Baseline (week 1) and at the end of the intervention (week 8). | Pulmonary function will be assessed using spirometry. Forced vital capacity (FVC), representing the maximum volume of air that can be forcibly exhaled after a full inspiration, will be measured in liters (L). |
| Secondary | Change in Forced Expiratory Volume in One Second (FEV1) | Baseline (week 1) and at the end of the intervention (week 8). | Pulmonary function will be assessed using spirometry. Forced expiratory volume in one second (FEV1), representing the volume of air forcibly exhaled during the first second, will be measured in liters (L). |
| Secondary | Change in FEV1/FVC Ratio | Baseline (week 1) and at the end of the intervention (week 8). | The FEV1/FVC ratio will be calculated by dividing forced expiratory volume in one second (FEV1) by forced vital capacity (FVC) and will be expressed as a percentage (%). |
| Secondary | Change in Peak Expiratory Flow (PEF) | Baseline (week 1) and at the end of the intervention (week 8). | Peak expiratory flow (PEF) will be assessed using spirometry and expressed in liters per second (L/s). |
| Secondary | Change in Respiratory Muscle Strength | Baseline (week 1) and at the end of the intervention (week 8). | Respiratory muscle strength will be assessed by measuring maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP). |
| Secondary | Change in Functional Exercise Capacity | Baseline (week 1) and at the end of the intervention (week 8). | Functional exercise capacity will be assessed using the Six-Minute Walk Test (6MWT). The total distance walked will be recorded in meters. |
| Secondary | Change in Sleep Quality | Baseline (week 1) and at the end of the intervention (week 8). | Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Total scores range from 0 to 21, with higher scores indicating poorer sleep quality. |
| Secondary | Change in Health-Related Quality of Life | Baseline (week 1) and at the end of the intervention (week 8). | Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36), which evaluates eight health dimensions. Scores range from 0 to 100, with higher scores indicating better health status. |
| Secondary | Change in Perceived Dyspnea | Baseline (week 1) and at the end of the intervention (week 8), during or immediately after the relevant activity or test. | Perceived dyspnea will be assessed using the Modified Borg Dyspnea Scale, which ranges from 0 (no breathlessness) to 10 (maximum breathlessness). |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913503
GET https://conductscience.org/api/trials/v1/NCT07913503/registered